Impaired endothelial function of the retinal vasculature in hypertensive patients

Stroke

Volumn 35, Issue 6, 2004, Pages 1289-1293

  Delles, Christian ^a   Michelson, Georg ^a   Harazny, Joanna ^a   Oehmer, Sebastian ^a   Hilgers, Karl F ^a   Schmieder, Roland E ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Angiotensins; Cerebrovascular circulation; Endothelium; Hypertension; Nitric oxide

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CANDESARTAN HEXETIL; N(G) METHYLARGININE; NITRIC OXIDE; PLACEBO;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; BRAIN CIRCULATION; CAPILLARY ENDOTHELIUM; CAPILLARY FLOW; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; HEMOPERFUSION; HUMAN; HYPERTENSION; INFUSION; LASER DOPPLER FLOWMETRY; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RECEPTOR BLOCKING; RETINA ARTERY; RETINA BLOOD VESSEL; RETINA CAPILLARY; TABLET FORMULATION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CAPILLARIES; CEREBRAL CORTEX; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; MALE; RETINAL ARTERY; TETRAZOLES; VASODILATION;

EID: 2542571205     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000126597.11534.3b     Document Type: Article

References (29)

1. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med. 1995;333:1392-1400.
2. Achard JM, Pruna A, Fernandez LA, Hottelart C, Mazouz H, Rosa A, Andrejak M, Fournier A. Prevention of stroke and cancer: could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors? Am J Hypertens. 1999;12:1050-1053.
3. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
4. Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension. 2000;35:501-506.
5. John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G, Schmieder RE. Rapid improvement of nitric oxide bioavailability after lipid lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol. 2001;37:1351-1358.
6. Delles C, Jacobi J, Schlaich MP, John S, Schmieder RE. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens. 2002;15:3-9.
7. Michelson G, Welzenbach J, Pal I, Harazny J. Automatic full field analysis of perfusion images gained by scanning laser Doppler flowmetry. Br J Ophthalmol. 1998;82:1294-1300.
8. Michelson G, Patzelt A, Harazny J. Flickering light increases retinal blood flow. Retina. 2002;22:336-343.
9. Buerk DG, Riva CE, Cranstoun SD. Nitric oxide has a vasodilatory role in cat optic nerve head during flicker stimuli. Microvasc Res. 1996;52:13-26.
10. Dorner GT, Garhofer G, Kiss B, Polska E, Polak K, Riva CE, Schmetterer L. Nitric oxide regulates retinal vascular tone in humans. Am J Physiol Heart Circ Physiol. 2003;285:H631-H636.
11. Mayer BX, Mensik C, Krishnaswami S, Derendorf H, Eichler HG, Schmetterer L, Wolzt M. Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. Br J Clin Pharmacol. 1999;47:539-544.
12. Schmetterer L, Findl O, Fasching P, Ferber W, Strenn K, Breiteneder H, Adam H, Eichler HG, Wolzt M. Nitric oxide and ocular blood flow in patients with IDDM. Diabetes. 1997;46:653-658.
13. 1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens. 2003;16:123-128.
14. Prasad A, Halcox JP, Waclawiw MA, Quyyumi AA. Angiotensin type I receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. J Am Coll Cardiol. 2001;38:1089-1095.
15. Delles C, Jacobi J, John S, Fleischmann I, Schmieder RE. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int. 2002;61:1462-1468.
16. 1-type angiotensin receptor in oxidative stress and atherogenesis: Part I: oxidative stress and atherogenesis. Circulation. 2002;105:393-396.
17. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264-269.
18. Jacobi J, Schneider MP, John S, Schmieder RE. Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. J Hypertens. 2002;20:525-530.
19. Hollenberg NK, Adams DF, Solomon H, Chenitz WR, Burger BM, Abrams HL, Merrill JP. Renal vascular tone in essential and secondary hypertension: hemodynamic and angiographic responses to vasodilators. Medicine (Baltimore). 1975;54:29-44.
20. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
21. Koss MC. Functional role of nitric oxide in regulation of ocular blood flow. Eur J Pharmacol. 1999;374:161-174.
22. Schmetterer L, Polak K. Role of nitric oxide in the control of ocular blood flow. Prog Retin Eye Res. 2001;20:823-847.
23. White RP, Deane C, Vallance P, Markus HS. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke. 1998;29:467-472.
24. White RP, Vallance P, Markus HS. Effect of inhibition of nitric oxide synthase on dynamic cerebral autoregulation in humans. Clin Sci (Lond). 2000;99:555-560.
25. Kidd GA, Dobrucki LW, Brovkovych V, Bohr DF, Malinski T. Nitric oxide deficiency contributes to large cerebral infarct size. Hypertension. 2000;35:1111-1118.
26. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000;31:2478-2486.
27. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke. 2002;33:2297-2303.
28. Walther T, Olah L, Harms C, Maul B, Bader M, Hortnagl H, Schultheiss HP, Mies G. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J. 2002;16:169-176.
29. Ito H, Takemori K, Kawai J, Suzuki T. AT1 receptor antagonist prevents brain edema without lowering blood pressure. Acta Neurochir Suppl. 2000;76:141-145.